Next Article in Journal
The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor
Next Article in Special Issue
Messenger RNA Life-Cycle in Cancer Cells: Emerging Role of Conventional and Non-Conventional RNA-Binding Proteins?
Previous Article in Journal
Bacterial Heterologous Expression System for Reconstitution of Chloroplast Inner Division Ring and Evaluation of Its Contributors
Previous Article in Special Issue
Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2018, 19(2), 545;

Alternative Splicing as a Target for Cancer Treatment

Centro de Investigaciones en Ciencias Microbiológicas, Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Puebla 72470, Mexico
Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1E 4K8, Canada
Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla 72470, Mexico
Centro de Investigación Biomédica de Oriente (CIBIOR), Instituto Mexicano del Seguro Social (IMSS), Metepec, Puebla 74360, Mexico
Instituto de Fisiología, Benemérita Universidad Autónoma de Puebla, Puebla 72470, Mexico
Author to whom correspondence should be addressed.
Received: 31 December 2017 / Revised: 29 January 2018 / Accepted: 29 January 2018 / Published: 11 February 2018
(This article belongs to the Special Issue Targeting Cancer through RNA Biology)
Full-Text   |   PDF [308 KB, uploaded 11 February 2018]


Alternative splicing is a key mechanism determinant for gene expression in metazoan. During alternative splicing, non-coding sequences are removed to generate different mature messenger RNAs due to a combination of sequence elements and cellular factors that contribute to splicing regulation. A different combination of splicing sites, exonic or intronic sequences, mutually exclusive exons or retained introns could be selected during alternative splicing to generate different mature mRNAs that could in turn produce distinct protein products. Alternative splicing is the main source of protein diversity responsible for 90% of human gene expression, and it has recently become a hallmark for cancer with a full potential as a prognostic and therapeutic tool. Currently, more than 15,000 alternative splicing events have been associated to different aspects of cancer biology, including cell proliferation and invasion, apoptosis resistance and susceptibility to different chemotherapeutic drugs. Here, we present well established and newly discovered splicing events that occur in different cancer-related genes, their modification by several approaches and the current status of key tools developed to target alternative splicing with diagnostic and therapeutic purposes. View Full-Text
Keywords: alternative splicing; cancer; diagnosis; therapeutics alternative splicing; cancer; diagnosis; therapeutics
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Martinez-Montiel, N.; Rosas-Murrieta, N.H.; Anaya Ruiz, M.; Monjaraz-Guzman, E.; Martinez-Contreras, R. Alternative Splicing as a Target for Cancer Treatment. Int. J. Mol. Sci. 2018, 19, 545.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top